Phenylahistin
Appearance
(Redirected from C20H22N4O2)
Names | |
---|---|
IUPAC name
(3S,6Z)-3-Benzyl-6-{[5-(2-methyl-3-buten-2-yl)-1H-imidazol-4-yl]methylene}-2,5-piperazinedione
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H22N4O2 | |
Molar mass | 350.422 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Phenylahistin is a metabolite produced by the fungus Aspergillus ustus[1] that belongs to a class of naturally occurring 2,5-diketopiperazines featuring a dehydrohistidine residue that exhibit important biological activities, such as anti-cancer or neurotoxic effects.[2]
Phenylahistin is a microtubule binding agent that exhibits cytotoxic activities against a wide variety of tumor cell lines.[3] A series of synthetic analogs were prepared to remove the chirality and optimize biological activity. These studies led to the potent anti-tumor agent plinabulin, which is active in multidrug-resistant (MDR) tumor cell lines.[4]
References
[edit]- ^ Kanoh K, Kohno S, Asari T, Harada T, Katada J, Muramatsu M, Kawashima H, Sekiya H, Uno I (1997). "(−)-Phenylahistin: A new mammalian cell cycle inhibitor produced by aspergillus ustus". Bioorganic & Medicinal Chemistry Letters. 7 (22): 2847–2852. doi:10.1016/S0960-894X(97)10104-4.
- ^ Borthwick AD (2012). "2,5-Diketopiperazines: Synthesis, Reactions, Medicinal Chemistry, and Bioactive Natural Products". Chemical Reviews. 112 (7): 3641–3716. doi:10.1021/cr200398y. PMID 22575049.
- ^ Kanoh K, Kohno S, Katada J, Hayash Y, Muramatsu M, Uno I (1999). "Antitumor activity of phenylahistin in vitro and in vivo". Bioscience, Biotechnology, and Biochemistry. 63 (6): 1130–1133. doi:10.1271/bbb.63.1130. PMID 10427703.
- ^ Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom ST (2006). "NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent". Anticancer Drugs. 17 (1): 25–31. doi:10.1097/01.cad.0000182745.01612.8a. PMID 16317287. S2CID 33272285.